Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Rein Therapeutics Inc. is currently managing 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. The prosecution landscape is diverse, as these 6 actions are spread across 6 distinct examiners. This ratio of 6 actions to 6 examiners suggests that the company's legal team must adapt to six different sets of examination preferences simultaneously.
Furthermore, the company interfaces with 6 distinct art units, indicating that its biotechnological research spans a wide array of specialized USPTO classifications. Shirley V Gembeh is the busiest examiner for the portfolio, though she is responsible for only 1 pending office action. The presence of 6 distinct art units suggests that the company's intellectual property is not confined to a single biotech niche. With Shirley V Gembeh handling 1 pending office action, the company maintains a balanced workload where no single examiner controls a significant portion of the pending matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 1 (17%) |
| Double-patenting only | 1 (17%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GEMBEH, SHIRLEY V | 1 | 63.1% | +33.8% |
| VARADARAJ, ARCHANA | 1 | 80.0% | +33.3% |
| ESPINOSA, CLAUDIA EDILMA | 1 | 50.9% | +56.1% |
| LIEB, JEANETTE M | 1 | 79.8% | +17.4% |
| MCCOLLUM, ANDREA K | 1 | 60.2% | +33.3% |
| LEE, JAE W | 1 | 65.6% | +38.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18702462 | MODIFIED CAVEOLIN-1 PEPTIDES FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE | VARADARAJ, ARCHANA | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18577028 | EPITHELIAL SODIUM CHANNEL (ENAC) INHIBITOR CONJUGATES AND METHODS FOR USE THEREOF | ESPINOSA, CLAUDIA EDILMA | — |
| 18547931 | BIOMARKERS FOR THE TREATMENT OF INTERSTITIAL LUNG DISEASE | MCCOLLUM, ANDREA K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19083757 | DRY POWDER FORMULATION OF CAVEOLIN-1 PEPTIDES AND METHODS OF USE THEREOF | GEMBEH, SHIRLEY V | — |
| 18702462 | MODIFIED CAVEOLIN-1 PEPTIDES FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE | VARADARAJ, ARCHANA | — |
| 18577028 | EPITHELIAL SODIUM CHANNEL (ENAC) INHIBITOR CONJUGATES AND METHODS FOR USE THEREOF | ESPINOSA, CLAUDIA EDILMA | — |
| 18571114 | MODIFIED CAVEOLIN-1 PEPTIDES FOR THE TREATMENT OF POST-ACUTE COVID-19 | LIEB, JEANETTE M | — |
| 18547931 | BIOMARKERS FOR THE TREATMENT OF INTERSTITIAL LUNG DISEASE | MCCOLLUM, ANDREA K | — |
| 18002420 | MODIFIED CAVEOLIN-1 PEPTIDES FOR THE TREATMENT OF PATHOGEN-INDUCED LUNG INJURY | LEE, JAE W | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1658 | 1 |
| 1624 | 1 |
| 1654 | 1 |
| 1674 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19083757 | DRY POWDER FORMULATION OF CAVEOLIN-1 PEPTIDES AND METHODS OF USE THEREOF | GEMBEH, SHIRLEY V | 1615 | DP | Non-Final OA | — | Pending | Mar 19, 2025 |
| 18702462 | MODIFIED CAVEOLIN-1 PEPTIDES FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE | VARADARAJ, ARCHANA | 1658 | §103§112DP | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18577028 | EPITHELIAL SODIUM CHANNEL (ENAC) INHIBITOR CONJUGATES AND METHODS FOR USE THEREOF | ESPINOSA, CLAUDIA EDILMA | 1624 | §103§112 | Non-Final OA | — | Pending | Jan 05, 2024 |
| 18571114 | MODIFIED CAVEOLIN-1 PEPTIDES FOR THE TREATMENT OF POST-ACUTE COVID-19 | LIEB, JEANETTE M | 1654 | §103§112DP | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18547931 | BIOMARKERS FOR THE TREATMENT OF INTERSTITIAL LUNG DISEASE | MCCOLLUM, ANDREA K | 1674 | §101§102§112 | Non-Final OA | — | Pending | Aug 25, 2023 |
| 18002420 | MODIFIED CAVEOLIN-1 PEPTIDES FOR THE TREATMENT OF PATHOGEN-INDUCED LUNG INJURY | LEE, JAE W | 1656 | §103 | Final Rejection | — | Pending | Dec 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRein Therapeutics Inc. has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
Shirley V Gembeh has the most, with 1 of Rein Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
